Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

BACKGROUND: Real-world data on transitioning to Immune Globulin Subcutaneous (Human) 20% solution (Ig20Gly) are limited. This study aimed to assess infusion parameters and experience of patients with primary (PID) or secondary immunodeficiencies (SID) transitioning to Ig20Gly in clinical practice in...

Descripción completa

Detalles Bibliográficos
Autores principales: Keith, Paul K., Cowan, Juthaporn, Kanani, Amin, Kim, Harold, Lacuesta, Gina, Lee, Jason K., Chen, Jie, Park, Michelle, Gladiator, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358831/
https://www.ncbi.nlm.nih.gov/pubmed/35934726
http://dx.doi.org/10.1186/s13223-022-00709-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358831/
https://www.ncbi.nlm.nih.gov/pubmed/35934726
http://dx.doi.org/10.1186/s13223-022-00709-8

Ejemplares similares